LAEKNA-B (02105.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec22

Laekang Pharmaceutical Completes First Dose Administration for LAE102 Phase I Multiple Dose Expansion Study in Obesity Treatment

00:17

Dec15

Cullerna Biotech Completes Phase III Clinical Trial Enrollment for LAE 002 and Enters into Exclusive License Agreement with Qilu Pharmaceutical

00:43

Nov14

Cullagenix Grants License to Qilu Pharmaceutical for Breast Cancer Candidate LAE002 in China

00:48

Nov12

LAEKA Pharmaceuticals Grants QiLu Pharmaceutical Exclusive License for LAE 002 Development and Commercialization in China

00:27

Sep30

DBS Research downgrades Laichai Medicine target price to HKD24.16 and reiterates 'Buy' rating

02:38

Sep29

Laekna, Inc. receives analyst ratings and target price

06:36

Schedules & Filings

Schedules

Filings

Aug13

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 2.468 M, Net Income -70.95 M, EPS -0.1889

Mar24

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 62.77 K, Net Income -58.83 M, EPS -0.1637

Aug16

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 218.13 K, Net Income -77.21 M, EPS -0.2168

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More